Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | CHKA | P35790 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 5/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTR1D | P28221 | 3/20 | 0.39 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TRPV6 | Q9H1D0 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31428496 | 0.82 | HRH3 (0.38) | HRH3CHKATSHRKMT2APDCD1LG2 | |
| SCHEMBL25728358 | 0.82 | HRH3 (0.49) | HRH3KCNH2CHKATSHRACHE | |
| SCHEMBL31428715 | 0.82 | HRH3 (0.49) | HRH3KCNH2TSHRCYP1A2 | |
| SCHEMBL31428922 | 0.81 | CHKA (0.60) | HRH3KCNH2CHKATSHRHTR1A | |
| SCHEMBL25728287 | 0.80 | CHKA (0.59) | HRH3KCNH2CHKAHTR1AKMT2A | |
| SCHEMBL27318436 | 0.80 | HRH3 (0.53) | HRH3KCNH2CHKAKMT2ACYP1A2 | |
| SCHEMBL31428611 | 0.79 | HRH3 (0.47) | HRH3KCNH2ACHE | |
| SCHEMBL30163574 | 0.79 | HRH3 (0.42) | HRH3KCNH2HTR1ACYP1A2 | |
| SCHEMBL24694886 | 0.77 | HRH3 (0.47) | HRH3KCNH2KMT2ACYP1A2MEN1 | |
| SCHEMBL30163474 | 0.74 | KMT2A (0.56) | HRH3KCNH2CHKAKMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | HRH3 2324/4885KCNH2 3703/4885CHKA 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.